# Development of a VesiVax HIV Vaccine Formulation

> **NIH NIH N44** · MOLECULAR EXPRESS, INC. · 2022 · $1,994,571

## Abstract

Particle-based Co-delivery of HIV immunogens as Next-generation HIV Vaccines: Tailored immunogens (such as Envs, monomers, native and/or native-like trimers, nucleic acids/RNA such as mRNAs, self-amplifying RNAs) combined with an effective multivalent antigenic display on nanoparticles for delivery may provide a strategy to promote strong and long-lived neutralizing antibody responses against HIV and direct affinity maturation toward HIV neutralizing antibodies. The objective of this contract is to evaluate the different co-delivery methods of a model HIV antigen using the VesiVax liposomal platform.

## Key facts

- **NIH application ID:** 10653678
- **Project number:** 75N93021C00027-P00003-9999-1
- **Recipient organization:** MOLECULAR EXPRESS, INC.
- **Principal Investigator:** SAM ON HO
- **Activity code:** N44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,994,571
- **Award type:** —
- **Project period:** 2022-08-01 → 2024-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10653678

## Citation

> US National Institutes of Health, RePORTER application 10653678, Development of a VesiVax HIV Vaccine Formulation (75N93021C00027-P00003-9999-1). Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/grant/nih/10653678. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*